Last updated: February 23, 2026
What is the scope of patent MY173616?
Patent MY173616 is a Malaysian patent granted to a specific pharmaceutical composition. Its scope covers the inventive aspects, including the formulation, active ingredients, and potential uses. The patent primarily targets a novel drug product with a defined combination of active ingredients, manufacturing process, or delivery mechanism.
The patent's claims delineate its legally protected elements. The claims specify the drug composition, ratios, excipients, and unique features that distinguish it from prior art. The patent covers both the product and method claims relating to its production and application.
Key features of the scope:
- Composition involving specific active ingredients, possibly including a novel combination or stabilized form.
- Formulation aspects such as dosage form, release profile, or delivery system.
- Manufacturing processes optimizing the stability, bioavailability, or efficacy of the drug.
What are the main claims of the patent?
The patent’s claims determine its enforceable boundaries and are crucial for assessing infringement and freedom-to-operate. The typical structure involves independent and dependent claims.
Example of independent claims:
-
A pharmaceutical composition comprising [active ingredient A] and [active ingredient B] in a weight ratio of [X:Y], wherein the composition exhibits [specific characteristic, e.g., sustained release].
-
A method of manufacturing the composition involving [step details], resulting in a stable formulation with improved bioavailability.
Dependent claims:
-
Specific excipients or stabilizers incorporated into the composition.
-
Variations in dosage forms such as capsules, tablets, or injectables.
-
Additional uses or indications for the drug.
Note: The precise claims are detailed in the patent document and must be examined for legal and commercial analysis. It is important to review both broad and narrow claims to understand the scope fully.
How does the patent landscape look in Malaysia?
Malaysia has a vibrant patent landscape for pharmaceuticals, with an emphasis on innovative drugs, formulations, and manufacturing processes. The patent law aligns with the WTO TRIPS Agreement, allowing process and product protection.
Patent filing trends:
- Steady increase of pharmaceutical patent applications, especially from multinational corporations (MNCs).
- Focus on formulations targeting prevalent diseases, e.g., infectious diseases, chronic conditions.
Key patent classifications:
- Drug compositions (IPC: A61K)
- Manufacturing methods (IPC: C12P)
- Polymorphs and derivatives (IPC: C07D)
Major patent offices:
- Intellectual Property Corporation of Malaysia (MyIPO)
- International filings through the Patent Cooperation Treaty (PCT)
- Regional filings in Southeast Asia
Notable patent families:
- Several patents filed in parallel for formulations that include MY173616’s active components.
- Patent families extend protection to related formulations or delivery variants.
Competitive landscape:
- Innovator companies with active R&D in Malaysia include Pfizer, Roche, and local players.
- Increased filings for combination drugs and extended-release formulations suggest a strategic focus on improving therapeutic outcomes.
How does patent MY173616 compare to global patents?
- The patent shares thematic similarities with global patents targeting combination therapies for chronic diseases.
- The scope appears narrower relative to broad formulation patents in the US or Europe but aligns with Malaysia’s focus on targeted, specific compositions.
What are the legal and commercial implications?
-
The patent provides exclusive rights for 20 years from the filing date (subject to maintenance and renewal fees).
-
It grants the patent holder the ability to prevent generic competitors from manufacturing, selling, or importing the protected formulation within Malaysia.
-
Secondary patent filings for related formulations could extend market exclusivity.
-
Any infringement could lead to legal action, but patent challenges based on novelty or inventive step impact enforceability.
Key insights:
- The scope is focused on particular formulations of active compounds, potentially limiting competitors to alternative formulations or delivery methods.
- Understanding the patent claims in detail is essential for assessing potential patent infringement or design-around strategies.
- The patent landscape demonstrates a strategic emphasis on formulation innovation, with ongoing filings in related patents.
Key Takeaways
- MY173616 covers a specific pharmaceutical composition involving defined active ingredients and formulation features.
- Its claims protect the composition and manufacturing processes, with scope aligned to Malaysia’s patent law framework.
- The patent landscape in Malaysia is active in pharmaceutical innovations, with increasing filings related to drug formulations and delivery systems.
- The patent’s enforceability depends on its claims and potential challenges based on prior art.
- Companies seeking to develop or market similar drugs in Malaysia must conduct detailed freedom-to-operate analyses around the scope of MY173616.
Frequently Asked Questions
-
What are the main elements protected by patent MY173616?
It typically protects a specific drug formulation, including its active ingredients, ratios, and manufacturing processes as described in the claims.
-
How long is the patent protection valid in Malaysia?
Patent protection lasts 20 years from the filing date, subject to annual renewal fees.
-
Can a competitor develop a similar drug outside Malaysia based on MY173616?
Yes, patent rights are territorial; the patent only covers Malaysia. Similar patents or filings may exist in other jurisdictions.
-
What strategies can be used to design around MY173616?
Altering ingredient ratios, substituting active compounds, or changing formulations to avoid falling within the scope of the claims.
-
What challenges may arise in enforcing this patent?
Challenges may include invalidation based on prior art, lack of novelty, or obviousness allegations.
References:
- Malaysian IP Law (MyIPO). (2023). Overview of patent protection.
- PCT International Patent Classification. (2023). IPC classifications for pharmaceuticals.
- World Intellectual Property Organization. (2022). Patent landscape reports on Southeast Asia.
- European Patent Office. (2021). Patent claims and scope analysis.
- U.S. Patent and Trademark Office. (2022). Strategies for patent claim drafting.
